ClinicalTrials.gg
CompletedNCT05579899Updated Mar 5, 2025Results posted

Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis

A Phase 2 interventional study of EVO101 in Atopic Dermatitis Eczema, sponsored by Evommune, Inc.. Completed at 21 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-05.

Sponsored by Evommune, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 639 studies in Dermatitis, Atopic with a site in United States — 78 open to participants now, 117 under way, 18 of them phase 3. Dermatitis, Atopic · United States.

Enrollment
247th of 544
119 · median 96
Started
2022
with 44 others
Phase 2
202 of 639
18 open now
Registered
480th of 639
by date

Among the 639 studies in Dermatitis, Atopic with a site in United States, this one is the 247th largest by enrollment of the 544 interventional ones that give a count, is one of 45 that started in 2022, is one of 202 in phase 2, and was the 480th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

78 of the 639 studies in Dermatitis, Atopic with a site in United States are open now. Recruiting first, the newest first:

73 more — sign in →

All 78 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 639 studies in Dermatitis, Atopic with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis

Read the detailed description

This is a Phase 2a safety and efficacy study of EVO101 Topical Cream, 0.1%, applied twice daily for 8 weeks in adults with mild-to moderate atopic dermatitis.

03

Conditions studied

  • Atopic Dermatitis Eczema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or non-pregnant, non-lactating females, age 18 years or older
  2. Chronic atopic dermatitis for at least 1 year
  3. IGA score of 2 or 3
  4. BSA of AD involvement of 4-12%
  5. EASI of 5-20

Exclusion criteria

Exclusion Criteria:

  1. Significant AD flare with 4 weeks
  2. Use of biologic therapy within 12 weeks
  3. Regular use of tanning booth within 4 weeks
  4. Skin condition that could interfere with study assessments
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    EVO101 Cream

    Active Treatment, BID, 8 weeks

    Drug: EVO101

  • Placebo comparator
    Vehicle Cream

    Vehicle Treatment, BID, 8 weeks

    Drug: EVO101

Interventions

  • DrugEVO101

    Topical Cream

06

What researchers measure

Primary outcomes

  1. Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8

    EASI assesses the extent and severity of atopic dermatitis. EASI is a composite index with scores ranging from 0 to 72. Higher values indicate more severe or extensive disease.

    Time frame: 8 weeks

Secondary outcomes

  1. Investigator Global Assessment (IGA) Response (Number of Participants With >= 2 Points Change From Baseline to Week 8)

    The IGA assesses the overall appearance and severity of atopic dermatitis using a 5-point scale \[0 (clear) to 4 (severe)\]. The outcome measures is reported as the number of participants achieving a reduction of 2 or greater on the IGA from baseline to Week 8.

    Time frame: 8 weeks

  2. Percent Body Surface Area (BSA) Affected by Atopic Dermatitis Over Time, Change From Baseline to Week 8

    BSA estimates the extent of atopic dermatitis involvement and is expressed as a percentage of total body surface area. The outcome measure describes the mean change from baseline in percent of the body surface area affected by AD.

    Time frame: 8 weeks

  3. Pruritus-NRS, Change From Baseline to Week 8

    The pruritus-NRS is an 11-point scale used by subjects to rate their worst itch severity over the past 24 hours with 0 indicating "no itch" and 10 indicating "worst itch imaginable".

    Time frame: 8 weeks

07

Results

Posted Mar 5, 2025

Participant flow

Participant flow — Overall Study
MilestoneEVO101 CreamVehicle Cream
Started6059
Completed5751
Not completed38
Withdrew: Lost to follow-up31
Withdrew: Adverse event03
Withdrew: Pregnancy01
Withdrew: Withdrawal by subject03

Outcome measures

PrimaryPercent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8

EASI assesses the extent and severity of atopic dermatitis. EASI is a composite index with scores ranging from 0 to 72. Higher values indicate more severe or extensive disease.

Time frame:
8 weeks
Reported as:
Mean · Percent change from baseline
Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8
Percent change from baselineEVO101 CreamVehicle Cream
Percent Change in Eczema Area and Severity Index (EASI) From Baseline to Week 8-43.5 ± 60.85-62.0 ± 38.78
SecondaryInvestigator Global Assessment (IGA) Response (Number of Participants With >= 2 Points Change From Baseline to Week 8)

The IGA assesses the overall appearance and severity of atopic dermatitis using a 5-point scale \[0 (clear) to 4 (severe)\]. The outcome measures is reported as the number of participants achieving a reduction of 2 or greater on the IGA from baseline to Week 8.

Time frame:
8 weeks
Reported as:
Count of participants · Participants
Investigator Global Assessment (IGA) Response (Number of Participants With >= 2 Points Change From Baseline to Week 8)
ParticipantsEVO101 CreamVehicle Cream
Yes2023
No3728
SecondaryPercent Body Surface Area (BSA) Affected by Atopic Dermatitis Over Time, Change From Baseline to Week 8

BSA estimates the extent of atopic dermatitis involvement and is expressed as a percentage of total body surface area. The outcome measure describes the mean change from baseline in percent of the body surface area affected by AD.

Time frame:
8 weeks
Reported as:
Mean · percentage of total body surface area
Percent Body Surface Area (BSA) Affected by Atopic Dermatitis Over Time, Change From Baseline to Week 8
percentage of total body surface areaEVO101 CreamVehicle Cream
Percent Body Surface Area (BSA) Affected by Atopic Dermatitis Over Time, Change From Baseline to Week 8-2.1 ± 6.45-3.5 ± 2.99
SecondaryPruritus-NRS, Change From Baseline to Week 8

The pruritus-NRS is an 11-point scale used by subjects to rate their worst itch severity over the past 24 hours with 0 indicating "no itch" and 10 indicating "worst itch imaginable".

Time frame:
8 weeks
Reported as:
Mean · Change in units on a scale
Pruritus-NRS, Change From Baseline to Week 8
Change in units on a scaleEVO101 CreamVehicle Cream
Pruritus-NRS, Change From Baseline to Week 8-2.5 ± 2.16-3.5 ± 2.55

Adverse events

Collected over 12 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
EVO101 Cream0/60 (0%)0/60 (0%)19/60 (31.7%)
Vehicle Cream0/58 (0%)0/58 (0%)30/58 (51.7%)
Most frequent other events
Most frequent other events
EventEVO101 CreamVehicle Cream
Application site pruritusSkin and subcutaneous tissue disorders8/6012/58
Application site oedemaSkin and subcutaneous tissue disorders3/6011/58
Application site erythemaSkin and subcutaneous tissue disorders4/6010/58
Application site drynessSurgical and medical procedures2/608/58
Application site painSkin and subcutaneous tissue disorders6/607/58
Application site exfoliationSkin and subcutaneous tissue disorders3/607/58

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)EVO101 CreamVehicle CreamTotal
<=18 years000
Between 18 and 65 years5155106
>=65 years9413
Sex: Female, Male
Sex: Female, Male(Participants)EVO101 CreamVehicle CreamTotal
Female373774
Male232245
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)EVO101 CreamVehicle CreamTotal
Hispanic or Latino202444
Not Hispanic or Latino393271
Unknown or Not Reported134
08

Study locations

21 sites
  • Saguaro Dermatology
    Phoenix, Arizona 85008, United States
  • Clinical Trials Institute of Northwest Arkansas
    Fayetteville, Arkansas 72703, United States
  • Northwest AR Clinical Trials Center, PLLC
    Rogers, Arkansas 72758, United States
  • California Dermatology & Clinical Research Institute
    Encinitas, California 92024, United States
  • Metropolis Dermatology
    Los Angeles, California 90017, United States
  • Dermatology Research Associate
    Los Angeles, California 90045, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Driven Research, LLC
    Coral Gables, Florida 33134, United States
  • Lenus Research and Medical Group
    Miami, Florida 33172, United States
  • Dawes Fretzin Clinical Research Group
    Indianapolis, Indiana 46250, United States
  • The Indiana Clinical Trials Center
    Plainfield, Indiana 46168, United States
  • Minnesota Clinical Study Center
    New Brighton, Minnesota 55112, United States
  • SkinSpecialists, LLC
    Omaha, Nebraska 69144, United States
  • JDR Dermatology Research, LLC
    Las Vegas, Nevada 89148, United States
  • Dermatology Consulting Services, PLLC
    High Point, North Carolina 27262, United States
  • Dermatologists of Southwest Ohio
    Mason, Ohio 45040, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223, United States
  • DermResearch
    Austin, Texas 78759, United States
  • J&S Studies, Inc
    College Station, Texas 77845, United States
  • Center for Clinical Studies, Ltd LLC
    Houston, Texas 77004, United States
  • Pariser Dermatology Specialists
    Norfolk, Virginia 23502, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results published, after deidentification (text, tables, figures, and appendices)

Supporting information: Study protocol

Time frame: Following publication

Access criteria: to be determined

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jul 2023, 10 months.

Results were first posted in Mar 2025, 1 year 7 months after primary completion.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 10 months is below that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2022
First posted
Oct 14, 2022
StartActual
Sep 27, 2022
Primary completionActual
Jul 27, 2023
CompletionActual
Jul 27, 2023
Results first posted
Mar 5, 2025
Last update
Mar 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05579899
Lead sponsor
Evommune, Inc.
Responsible party
Sponsor
First posted
Oct 14, 2022
Start date
Sep 27, 2022
Primary completion
Jul 27, 2023
Completion
Jul 27, 2023
Results posted
Mar 5, 2025
Last update
Mar 5, 2025

Study contacts

Eugene Bauer, MD
study director · Evommune, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion